Trial Profile
An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Feb 2020
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions
- Acronyms AHEAD-G202
- 05 Jun 2018 According to results presented at 54th Annual Meeting of the American Society of Clinical Oncology, 391 patients were enrolled between Mar 2015 and Dec 2017.
- 05 Jun 2018 Results (n=391) presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 20 Jan 2018 Results (n=326) assessing the safety and efficacy of apatinib in the real world with wider inclusion criteria, presented at the 2018 Gastrointestinal Cancers Symposium.